Profil
Jean Jacques Mention is currently the Chief Business Officer at OSE Immunotherapeutics SA. Prior to this, he held positions as Director of Business Development at Axenis SAS and Head of Business Development at genOway SA.
Aktive Positionen von Jean Jacques Mention
| Unternehmen | Position | Beginn |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Jean Jacques Mention
| Unternehmen | Position | Ende |
|---|---|---|
| GENOWAY | Corporate Officer/Principal | - |
Axenis SAS
 Axenis SAS BiotechnologyHealth Technology Part of genOway SA, Axenis SAS develops gene technology and products. The private company is based in Paris, France. Axenis was acquired by genOway SA on September 04, 2018 for $0.23 million. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GENOWAY | Health Technology |
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Axenis SAS
Axenis SAS BiotechnologyHealth Technology Part of genOway SA, Axenis SAS develops gene technology and products. The private company is based in Paris, France. Axenis was acquired by genOway SA on September 04, 2018 for $0.23 million. | Health Technology |
